Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX in Metastatic High Grade GEP-NEC
NCT03042780Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2017
- Primary completion
- Jan 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), sponsored by Moffitt Cancer Center. Started Feb 2017; status: terminated.
02
Drugs
oxaliplatinfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracil
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on NCT03042780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042780.